Genomic Valley Biotech share news and announcements
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹35.92.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 15 Aug 2026
- 567.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 15 Aug 2026
- 0.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 15 Aug 2026
- 0.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,994
Genomic Valley Biotech share news and announcements
489 announcements, routine notices left out, newest first. Page 4 of 10.
Feb 2023
Jan 2023
Dec 2022
Nov 2022
4 Nov · Board meeting
Meeting on 12 Nov 2022: quarterly results
Oct 2022
14 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Aug 2022
Jul 2022
14 Jul · Board meeting
Meeting on 20 Jul 2022: quarterly results
Jun 2022
13 Jun · Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31.03.2022
May 2022
28 May · Announcement under Regulation 30 (LODR)-Meeting Updates
20 May · Board meeting
Meeting on 28 May 2022: audited results and quarterly results13 May · Intimation Regarding The Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144
13 May · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Apr 2022
26 Apr · Intimation Regarding The Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144
15 Apr · Certificate Pursuant To Regulation 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
7 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 07 Apr · Submission Of Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Feb 2022
12 Feb · Revised Policy On Related Party Transactions
2 Feb · Board meeting
Meeting on 12 Feb 2022: quarterly results
Jan 2022
12 Jan · Shareholding for the Period Ended December 31, 2021
Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click ....11 Jan · Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 01 Jan · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly <a href="https://www.bseindia.com/stock-share-price/meetings/voting-results/539206 ....
Dec 2021
8 Dec · Reg. 34 (1) Annual Report